Work

Corrigendum

Year: 2021
Type: erratum
Abstract: In the article by Ying Cheng et al., the authors have noticed that there is a mistake in Figure 1B (hazard ratio data) due to copying error and in Table 2 (SCC part) due to miscalculation error.The authors have mistakenly put the incorrect values in Figure 1B (hazard ratio data) and also the relevant values are revised in the section under Discussion in text part.The correct version of Figure 1B is displayed below: Revised relevant values in the text are as the followings:-DISCUSSION (page 2626, left column, line 4) In this subgroup analysis, anlotinib significantly improved PFS not only in ACC patients (5.5 months vs 1.4 months; HR: 0.23; 95% CI: 0.17-0.30)but also in SCC patients (4.8 months vs 2.7 months, HR: 0.43; 95% CI: 0.18-0.59).OS was improved significantly in ACC patients (9.6 months vs 6.9 months; HR: 0.68; 95% CI: 0.48-0.88),while it was prolonged without a statistically significant difference in SCC patients (10.7 months vs 6.5 months; HR: 0.75; 95% CI: 0.43-1.25).
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,025
OpenAlex ID: W4229742193
Cites: 1
Cited by:
Related to: 7